Synmosa Biopharma: The Board of Directors of Synmosa decides to increase the share capital by recapitalization of results







Close

Provided by: SYNMOSA BIOPHARMA CORPORATION

SEQ_NO

4

announcement date

2022/03/29

Announcement time

15:29:32

Topic

 The Board of Synmosa resolves to
increase capital stock by earnings  recapitalization

Date of events

2022/03/29

What item it responds to

paragraph 11

Declaration

1.Date of the board of directors resolution:2022/03/29
2.Source of capital increase funds:profit for fiscal 2021
3.Whether to adopt shelf registration
  (Yes, please state issuance period/No):No
4.Total monetary value of the issuance and number of shares issued (shares
 issued not including those distributed to employees if consisting in
 capital increase from earnings or capital surplus):
30,016,520 shares,AMOUT NTD 300,165,200
5.If adopting shelf registration, monetary value and number of shares
to be issued this time:Not applicable
6.The remaining monetary value and shares after this issuance when
adopting shelf registration:Not applicable
7.Par value per share:NTD $10
8.Issue price:Not applicable
9.Number of shares subscribed for by or allocated to employees:
Not applicable
10.Number of shares publicly sold:Not applicable
11.Ratio of shares subscribed by or allotted as stock
dividends to existing shareholders:
100 share distributed gratis per 1,000 share
12.Handling method for fractional shares and shares
unsubscripted for by the deadline:
If the stock dividends include any fractional shares which are
less than one full share, the shareholders of two or more may
arrange for pooling together of their fractional shares to form
one full share and register the same under the name of one of the
shareholders within 5 days after the ex-rights date. For the
fractional shares which cannot be pooled within the specified period,
such remainder will be subscribed by designated individuals arranged
by the Chairman .
13.Rights and obligations of these newly issued shares:
The same as the issued and existing shares.
14.Utilization of the funds from the capital increase:
Not applicable
15.Any other matters that need to be specified:
(1)If the outstanding shares changed result in the
distributing ratio of stock dividends changed,
the final ratio will be determined fully by the Board authorized
by Shareholders'Meeting.
(2)If the plan of increasing capital stock is changed by the
authorities, it is determined fully to chang by the Board as
authorized by the Shareholders' Meeting.
(3)The ex-rights date will be determined fully by the Board as
authorized by the Shareholders' Meeting after the capital stock
increase is approved by the authorities.

Warning

Synmosa Biopharma Company published this content on March 29, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, on March 29, 2022 07:43:02 UTC.

Public now 2022

All news from SYNMOSA BIOPHARMA CORPORATION

Sale 2020 3,038 million
105 million
105 million
Net result 2020 638M
22.1M
22.1M
Net debt 2020 2,956 million
102 million
102 million
2020 PER ratio 10.4x
2020 performance 1.19%
Capitalization 7,387 million
256 million
256 million
EV / Sales 2019 3.09x
EV / Sales 2020 3.22x
# of employees
Floating 69.7%

Chart SYNMOSA BIOPHARMA CORPORATION


Duration :

Period :




Synmosa Biopharma Corporation Technical Analysis Chart |  MarketScreener

Trends in Technical Analysis SYNMOSA BIOPHARMA CORPORATION

Short term Middle term Long term
Tendencies Neutral Bullish Bullish



Evolution of the income statement


Sallie R. Loera